{"drugs":["Fulvicin P\/G","Gris-PEG","Griseofulvin, Ultramicrocrystalline"],"mono":{"0":{"id":"264170-s-0","title":"Generic Names","mono":"Griseofulvin, Ultramicrocrystalline"},"1":{"id":"264170-s-1","title":"Dosing and Indications","sub":{"0":{"id":"264170-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Onychomycosis due to dermatophyte:<\/b> 750 mg ORALLY in divided doses for at least 4 months (fingernails) or at least 6 months (toenails) or until infection clears<\/li><li><b>Tinea barbae:<\/b> 375 mg ORALLY daily as a single dose or in divided doses until infection has cleared<\/li><li><b>Tinea capitis:<\/b> 375 mg ORALLY daily as a single dose or in divided doses for 4 to 6 weeks or until infection clears<\/li><li><b>Tinea corporis:<\/b> 375 mg ORALLY daily as a single dose or in divided doses for 2 to 4 weeks or until infection clears<\/li><li><b>Tinea cruris:<\/b> 375 mg ORALLY daily as a single dose or in divided doses until infection has cleared<\/li><li><b>Tinea pedis:<\/b> 750 mg ORALLY in divided doses for 4 to 8 weeks or until infection clears<\/li><\/ul>"},"1":{"id":"264170-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Onychomycosis due to dermatophyte:<\/b> (35 to 60 pounds) 125 to 187.5 mg daily for at least 4 months (fingernails) or at least 6 months (toenails) or until infection clears<\/li><li><b>Onychomycosis due to dermatophyte:<\/b> (greater than 60 pounds) 187.5 to 375 mg daily for at least 4 months (fingernails) or at least 6 months (toenails) or until infection clears<\/li><li><b>Tinea barbae:<\/b> (35 to 60 pounds) 125 to 187.5 mg ORALLY once daily until infection has cleared<\/li><li><b>Tinea barbae:<\/b> (greater than 60 pounds 187.5 to 375 mg ORALLY once daily until infection has cleared<\/li><li><b>Tinea capitis:<\/b> (35 to 60 pounds) 125 to 187.5 mg ORALLY once daily for 4 to 6 weeks or until infection clears<\/li><li><b>Tinea capitis:<\/b> (greater than 60 pounds) 187.5 to 375 mg ORALLY once daily for 4 to 6 weeks or until infection clears<\/li><li><b>Tinea corporis:<\/b> (35 to 60 pounds) 125 to 187.5 mg ORALLY once daily for 2 to 4 weeks or until infection clears<\/li><li><b>Tinea corporis:<\/b> (greater than 60 pounds) 187.5 to 375 mg ORALLY once daily for 2 to 4 weeks or until infection clears<\/li><li><b>Tinea cruris:<\/b> (35 to 60 pounds) 125 to 187.5 mg ORALLY once daily until infection has cleared<\/li><li><b>Tinea cruris:<\/b> (greater than 60 pounds) 187.5 to 375 mg ORALLY once daily until infection has cleared<\/li><li><b>Tinea pedis:<\/b> (35 to 60 pounds) 125 to 187.5 mg ORALLY once daily for 4 to 8 weeks or until infection clears<\/li><li><b>Tinea pedis:<\/b> (greater than 60 pounds) 187.5 to 375 mg ORALLY once daily for 4 to 8 weeks or until infection clears<\/li><\/ul>"},"3":{"id":"264170-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Onychomycosis due to dermatophyte<\/li><li>Tinea barbae<\/li><li>Tinea capitis<\/li><li>Tinea corporis<\/li><li>Tinea cruris<\/li><li>Tinea pedis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Lichen planus, Cutaneous<br\/>"}}},"3":{"id":"264170-s-3","title":"Contraindications\/Warnings","sub":[{"id":"264170-s-3-9","title":"Contraindications","mono":"<ul><li>hepatocellular failure<\/li><li>hypersensitivity to griseofulvin<\/li><li>porphyria<\/li><li>pregnancy<\/li><\/ul>"},{"id":"264170-s-3-10","title":"Precautions","mono":"<ul><li>alcohol use; griseofulvin may potentiate effects (eg, tachycardia, flush)<\/li><li>hepatotoxicity (jaundice and elevation in ALT, AST, and bilirubin), including serious and fatal cases, has been reported; monitoring recommended; discontinuation may be necessary<\/li><li>lupus erythematosus or lupus-like syndromes have been reported<\/li><li>penicillin allergy; potential for cross-sensitivity with penicillin<\/li><li>photosensitivity may occur; avoid excessive exposure to sunlight<\/li><li>serious skin reactions (eg, Stevens-Johnson syndrome and toxic epidermal necrolysis) and erythema, including serious and fatal cases, have been reported; discontinuation if severe skin reactions occur<\/li><\/ul>"},{"id":"264170-s-3-11","title":"Pregnancy Category","mono":"Griseofulvin: B3 (AUS)<br\/>"},{"id":"264170-s-3-12","title":"Breast Feeding","mono":"<ul><li>Griseofulvin: WHO: WHO documentation states insufficient data.<\/li><li>Griseofulvin: Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}]},"4":{"id":"264170-s-4","title":"Drug Interactions","sub":{"2":{"id":"264170-s-4-15","title":"Moderate","mono":"<ul><li>Desogestrel (established)<\/li><li>Dienogest (established)<\/li><li>Drospirenone (established)<\/li><li>Estradiol Cypionate (established)<\/li><li>Estradiol Valerate (established)<\/li><li>Ethinyl Estradiol (established)<\/li><li>Ethynodiol Diacetate (established)<\/li><li>Etonogestrel (established)<\/li><li>Levonorgestrel (established)<\/li><li>Medroxyprogesterone Acetate (established)<\/li><li>Mestranol (established)<\/li><li>Norelgestromin (established)<\/li><li>Norethindrone (established)<\/li><li>Norgestimate (established)<\/li><li>Norgestrel (established)<\/li><li>Phenobarbital (probable)<\/li><li>Warfarin (probable)<\/li><\/ul>"}}},"5":{"id":"264170-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Photosensitivity, Rash, Urticaria<\/li><li><b>Gastrointestinal:<\/b>Diarrhea, Nausea, Vomiting<\/li><li><b>Neurologic:<\/b>Headache<\/li><\/ul><b>Serious<\/b><br\/><b>Neurologic:<\/b>Acroparesthesia (rare)<br\/>"},"6":{"id":"264170-s-6","title":"Drug Name Info","sub":{"0":{"id":"264170-s-6-17","title":"US Trade Names","mono":"<ul><li>Fulvicin P\/G<\/li><li>Gris-PEG<\/li><\/ul>"},"2":{"id":"264170-s-6-19","title":"Class","mono":"Antifungal<br\/>"},"3":{"id":"264170-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"264170-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"9":{"id":"264170-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>swallow whole or may crush and sprinkle over 1 tablespoonful of applesauce; swallow immediately without chewing <br\/>"},"10":{"id":"264170-s-10","title":"Monitoring","mono":"<ul><li>negative culture or improvement of clinical signs and symptoms of infection<\/li><li>hematopoietic, hepatic, and renal function; periodically during therapy<\/li><\/ul>"},"11":{"id":"264170-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Tablet: 125 MG, 250 MG<br\/><\/li><li><b>Fulvicin P\/G<\/b><br\/>Oral Tablet: 330 MG<br\/><\/li><li><b>Griseofulvin Ultramicrosize<\/b><br\/>Oral Tablet: 125 MG, 250 MG<br\/><\/li><li><b>Gris-PEG<\/b><br\/>Oral Tablet: 125 MG, 250 MG<br\/><\/li><\/ul>"},"13":{"id":"264170-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause sun-sensitivity. Advise patient to use sunscreen and avoid tanning beds.<\/li><li>Adverse effects to a fetus may be caused by either male or female patients receiving treatment with this drug. Emphasize the use of reliable contraception to patient. This applies during treatment and up to 1 month post therapy for women and 6 months post therapy for men.<\/li><li>This drug may cause rash, urticaria, diarrhea, nausea, vomiting, or headache.<\/li><\/ul>"}}}